A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects

NCT00813020 · Completed

Last updated 2026-05-28

This clinical trial is testing three different doses of the medication NN9535 in healthy adult men to see how the body absorbs and processes it over time.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 44 people

Who can join Ages 18–55 · male only

Timeline Started 2009-01 · est. completion 2009-04

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT00813020 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this clinical trial is to investigate whether differences exist between three different concentrations of the drug, NN9535, administered in healthy male subjects in equal doses.

Treatments tested

semaglutide Drug

Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
semaglutide Drug

Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
semaglutide also known as NN9535 Drug

Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses

Main thing measured	AUC0-8 (NN9535), the area under the plasma NN9535 plasma-concentration-time curve in the interval 0-8 after investigational medicinal product administration
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00813020 ↗